Raras
Buscar doenças, sintomas, genes...
Síndrome Li-Fraumeni
ORPHA:524CID-10 · C97CID-11 · 2B51.YOMIM 151623DOENÇA RARA

É uma condição genética hereditária (transmitida de pais para filhos) que aumenta muito a chance de uma pessoa ter diversos tipos de câncer. Ela é causada por alterações (mutações) no gene TP53. Entre os tipos de câncer que podem surgir estão: câncer de mama, sarcomas de tecidos moles, osteossarcomas (câncer nos ossos), tumores cerebrais, carcinoma adrenocortical (câncer na glândula adrenal) e leucemias.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

É uma condição genética hereditária (transmitida de pais para filhos) que aumenta muito a chance de uma pessoa ter diversos tipos de câncer. Ela é causada por alterações (mutações) no gene TP53. Entre os tipos de câncer que podem surgir estão: câncer de mama, sarcomas de tecidos moles, osteossarcomas (câncer nos ossos), tumores cerebrais, carcinoma adrenocortical (câncer na glândula adrenal) e leucemias.

Pesquisas ativas
13 ensaios
25 total registrados no ClinicalTrials.gov
Publicações científicas
1.617 artigos
Último publicado: 2026 Apr 15
Medicamentos
1 registrados
METFORMIN

Tem tratamento?

1 medicamento registrado
Ver detalhes, fases e interações →
METFORMIN

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
Unknown
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
7.0
United Kingdom
Início
All ages
🏥
SUS: Sem cobertura SUSScore: 0%
CID-10: C97
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🩸
Sangue
4 sintomas
🫃
Digestivo
4 sintomas
🦴
Ossos e articulações
3 sintomas
🫘
Rins
2 sintomas
🫁
Pulmão
2 sintomas
💪
Músculos
1 sintomas

+ 23 sintomas em outras categorias

Características mais comuns

90%prev.
Neoplasia
Muito frequente (99-80%)
55%prev.
Carcinoma de mama
Frequente (79-30%)
17%prev.
Carcinoma do plexo coroide
Ocasional (29-5%)
17%prev.
Carcinoma adrenocortical
Ocasional (29-5%)
17%prev.
Glioblastoma multiforme
Ocasional (29-5%)
17%prev.
Linfoma
Ocasional (29-5%)
41sintomas
Muito frequente (1)
Frequente (1)
Ocasional (14)
Muito raro (19)
Sem dados (6)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 41 características clínicas mais associadas, ordenadas por frequência.

NeoplasiaNeoplasm
Muito frequente (99-80%)90%
Carcinoma de mamaBreast carcinoma
Frequente (79-30%)55%
Carcinoma do plexo coroideChoroid plexus carcinoma
Ocasional (29-5%)17%
Carcinoma adrenocorticalAdrenocortical carcinoma
Ocasional (29-5%)17%
Glioblastoma multiforme
Ocasional (29-5%)17%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico1.617PubMed
Últimos 10 anos200publicações
Pico2025106 papers
Linha do tempo
2026Hoje · 2026🧪 2002Primeiro ensaio clínico📈 2025Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

4 genes identificados com associação a esta condição. Padrão de herança: Autosomal dominant.

CHEK2Serine/threonine-protein kinase Chk2Candidate gene tested inTolerante
FUNÇÃO

Serine/threonine-protein kinase which is required for checkpoint-mediated cell cycle arrest, activation of DNA repair and apoptosis in response to the presence of DNA double-strand breaks. May also negatively regulate cell cycle progression during unperturbed cell cycles. Following activation, phosphorylates numerous effectors preferentially at the consensus sequence [L-X-R-X-X-S/T] (PubMed:37943659). Regulates cell cycle checkpoint arrest through phosphorylation of CDC25A, CDC25B and CDC25C, in

LOCALIZAÇÃO

NucleusNucleus, PML bodyNucleus, nucleoplasm

VIAS BIOLÓGICAS (2)
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaksG2/M DNA damage checkpoint
MECANISMO DE DOENÇA

Tumor predisposition syndrome 4

A disorder characterized by an increased risk for developing various types of benign and/or malignant neoplasms that arise at an accelerated rate and in different organs.

OUTRAS DOENÇAS (6)
obsolete Li-Fraumeni syndrome 2bone osteosarcomaprostate cancer, hereditaryhereditary breast ovarian cancer syndrome
HGNC:16627UniProt:O96017
CDKN2ACyclin-dependent kinase inhibitor 2ACandidate gene tested inRestrito
FUNÇÃO

Acts as a negative regulator of the proliferation of normal cells by interacting strongly with CDK4 and CDK6. This inhibits their ability to interact with cyclins D and to phosphorylate the retinoblastoma protein

LOCALIZAÇÃO

CytoplasmNucleus

VIAS BIOLÓGICAS (8)
Regulation of TP53 DegradationOncogene Induced SenescenceOxidative Stress Induced SenescenceStabilization of p53Regulation of RUNX3 expression and activity
OUTRAS DOENÇAS (10)
B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)familial melanomaLi-Fraumeni syndromefamilial atypical multiple mole melanoma syndrome
HGNC:1787UniProt:P42771
TP53Cellular tumor antigen p53Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Multifunctional transcription factor that induces cell cycle arrest, DNA repair or apoptosis upon binding to its target DNA sequence (PubMed:11025664, PubMed:12524540, PubMed:12810724, PubMed:15186775, PubMed:15340061, PubMed:17317671, PubMed:17349958, PubMed:19556538, PubMed:20673990, PubMed:20959462, PubMed:22726440, PubMed:24051492, PubMed:24652652, PubMed:35618207, PubMed:36634798, PubMed:38653238, PubMed:9840937). Acts as a tumor suppressor in many tumor types; induces growth arrest or apop

LOCALIZAÇÃO

CytoplasmNucleusNucleus, PML bodyEndoplasmic reticulumMitochondrion matrixCytoplasm, cytoskeleton, microtubule organizing center, centrosome

VIAS BIOLÓGICAS (10)
TP53 Regulates Metabolic GenesRegulation of TP53 ExpressionRegulation of TP53 DegradationOncogene Induced SenescenceOxidative Stress Induced Senescence
EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
73.0 TPM
Skin Sun Exposed Lower leg
37.0 TPM
Skin Not Sun Exposed Suprapubic
35.2 TPM
Fibroblastos
32.9 TPM
Ovário
32.4 TPM
OUTRAS DOENÇAS (29)
Li-Fraumeni syndromenasopharyngeal carcinoma, susceptibility to, 1hepatocellular carcinomafamilial pancreatic carcinoma
HGNC:11998UniProt:P04637
MDM2E3 ubiquitin-protein ligase Mdm2Modifying germline mutation inAltamente restrito
FUNÇÃO

E3 ubiquitin-protein ligase that mediates ubiquitination of p53/TP53, leading to its degradation by the proteasome (PubMed:29681526). Inhibits p53/TP53- and p73/TP73-mediated cell cycle arrest and apoptosis by binding its transcriptional activation domain. Also acts as a ubiquitin ligase E3 toward itself and ARRB1. Permits the nuclear export of p53/TP53. Promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma RB1 protein. Inhibits DAXX-mediated apoptosis by inducing its

LOCALIZAÇÃO

Nucleus, nucleoplasmCytoplasmNucleus, nucleolusNucleus

VIAS BIOLÓGICAS (6)
Regulation of TP53 DegradationAKT phosphorylates targets in the cytosolDegradation of CDH1NPAS4 regulates expression of target genesConstitutive Signaling by AKT1 E17K in Cancer
EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
32.5 TPM
Linfócitos
29.9 TPM
Pulmão
18.3 TPM
Tecido adiposo
17.9 TPM
Nervo tibial
16.0 TPM
OUTRAS DOENÇAS (5)
lessel-kubisch syndromeLi-Fraumeni syndromededifferentiated liposarcomawell-differentiated liposarcoma
HGNC:6973UniProt:Q00987

Medicamentos e terapias

METFORMINPhase 1

Mecanismo: Mitochondrial complex I (NADH dehydrogenase) inhibitor

Ver mais no OpenTargets

Variantes genéticas (ClinVar)

2,241 variantes patogênicas registradas no ClinVar.

🧬 MDM2: GRCh37/hg19 12q15-21.1(chr12:68168330-72795051)x1 ()
🧬 MDM2: GRCh37/hg19 12q14.1-15(chr12:61755618-70035424)x1 ()
🧬 MDM2: NM_002392.6(MDM2):c.613C>G (p.Leu205Val) ()
🧬 MDM2: NM_002392.6(MDM2):c.1114A>G (p.Ile372Val) ()
🧬 MDM2: GRCh37/hg19 12q14.2-15(chr12:64609458-70352103)x1 ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 2,888 variantes classificadas pelo ClinVar.

2744
144
VUS (95.0%)
Benigna (5.0%)
VARIANTES MAIS SIGNIFICATIVAS
TP53: NM_000546.6(TP53):c.991_993+64dup [Uncertain significance]
TP53: NM_000546.6(TP53):c.274C>A (p.Pro92Thr) [Uncertain significance]
TP53: NM_000546.6(TP53):c.217G>C (p.Val73Leu) [Uncertain significance]
TP53: NM_000546.6(TP53):c.44G>T (p.Ser15Ile) [Uncertain significance]
TP53: NM_000546.6(TP53):c.88A>T (p.Asn30Tyr) [Uncertain significance]

Vias biológicas (Reactome)

50 vias biológicas associadas aos genes desta condição.

Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks Regulation of TP53 Activity through Phosphorylation Regulation of TP53 Degradation Regulation of TP53 Activity through Methylation G2/M DNA damage checkpoint Stabilization of p53 Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex Oxidative Stress Induced Senescence Senescence-Associated Secretory Phenotype (SASP) Oncogene Induced Senescence Cyclin D associated events in G1 Transcriptional Regulation by VENTX Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6 Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6 Regulation of MITF-M-dependent genes involved in cell cycle and proliferation Activation of NOXA and translocation to mitochondria Activation of PUMA and translocation to mitochondria Pre-NOTCH Transcription and Translation Formation of Senescence-Associated Heterochromatin Foci (SAHF) DNA Damage/Telomere Stress Induced Senescence SUMOylation of transcription factors Autodegradation of the E3 ubiquitin ligase COP1 Association of TriC/CCT with target proteins during biosynthesis Pyroptosis TP53 Regulates Metabolic Genes Ub-specific processing proteases Ovarian tumor domain proteases Interleukin-4 and Interleukin-13 signaling TP53 Regulates Transcription of DNA Repair Genes TP53 Regulates Transcription of Genes Involved in Cytochrome C Release TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain TP53 Regulates Transcription of Caspase Activators and Caspases TP53 Regulates Transcription of Death Receptors and Ligands TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest Regulation of TP53 Expression Regulation of TP53 Activity through Acetylation Regulation of TP53 Activity through Association with Co-factors AKT phosphorylates targets in the cytosol SUMOylation of ubiquitinylation proteins Trafficking of AMPA receptors Constitutive Signaling by AKT1 E17K in Cancer Regulation of RUNX3 expression and activity Signaling by ALK fusions and activated point mutants Degradation of CDH1 NPAS4 regulates expression of target genes

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
3Fase 31
2Fase 21
1Fase 12
·Pré-clínico17
Medicamentos catalogadosEnsaios clínicos· 1 medicamento · 20 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Síndrome Li-Fraumeni

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

11 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

25 ensaios clínicos encontrados, 13 ativos.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

🥈Melhor nível de evidência: Observacional
Timeline de publicações
890 papers (10 anos)

Mostrando amostra de 200 publicações de um total de 890

#1

Back pain in an adolescent: not just a sore spine!

Ecancermedicalscience2026

Acute lymphoblastic leukaemia (ALL) can mimic diverse musculoskeletal conditions, often resulting in diagnostic delays. Genetic predisposition to various cancer syndromes further complicates the clinical picture, influencing disease presentation and treatment response. We report an adolescent boy who presented with a 2-month history of episodic fever, persistent low back pain and non-migratory joint pain, with a history of growth failure, developmental delay and seizures since childhood. There was a history of malignancy in multiple family members. The clinical examination revealed no features suggestive of systemic involvement. The joint examination revealed swelling around the knee joints. Initial work-up for chronic infections and autoimmune diseases was negative. Magnetic resonance imaging spine findings of multiple T2 hyperintense lesions warranted a bone marrow examination, which confirmed the diagnosis of Ph+ B- ALL. Molecular analysis revealed a pathogenic heterozygous missense variant in the TP53 gene, leading to the diagnosis of Li-Fraumeni syndrome. This case highlights the importance of recognizing musculoskeletal symptoms as a potential presentation of ALL. Early consideration of leukaemia in the differential diagnosis can prevent delays in treatment, ultimately improving outcomes.

#2

Tumor patterns and cancer risk in carriers of TP53 exonic germline variants that alter mRNA splicing.

European journal of human genetics : EJHG2026 Mar 03

Abnormal RNA splicing is an underrecognized driver of pathogenicity in germline TP53 - the cause of Li-Fraumeni syndrome (LFS). We re-evaluated exonic single-nucleotide variants (SNVs) that yield missense or synonymous changes for spliceogenic effects by integrating SpliceAI prediction, in-vitro minigene assays, and analysis of tumor RNA-seq from TCGA, and assessed genotype-phenotype correlations using clinical data from multiple databases and national registries. We identified 58 spliceogenic exonic SNVs (SE-SNVs) across the TP53 gene (40 missense, 18 synonymous). Experimental validation confirmed aberrant splicing for 15 out of 17 tested variants, most often through cryptic splice-site activation that introduced frameshifts and premature termination. Clinically, carriers of SE-SNVs previously considered as mild or of low-pathogenicity by protein-based assays showed earlier onset and LFS-signature cancers, indicating that splicing disruption can override amino-acid effects. The recurrent c.375 G > A (p.(Thr125 = )) showed heterogeneous effect: with both childhood/adolescent and adult onset, consistent with partial, variable retention of canonical splicing. These data reveal a substantial burden of spliceogenic pathogenicity in TP53 and strong support integrating splicing prediction, functional validation, and transcript-level evidence into variant interpretation and risk stratification in LFS.

#3

Evaluation of non-canonical p53 functions in DNA replication and recombination for variant classification.

Cell death &amp; disease2026 Feb 28

Pathogenic germline TP53 variants predispose to diverse Li-Fraumeni syndrome (LFS) phenotypes and a broad cancer spectrum, whereby carriers of hypomorphic variants cluster in a cohort with attenuated disease onset and an overrepresentation of breast cancer (BC). Recently, functional assays have gained importance among the criteria used to predict the pathogenicity of hereditary breast and ovarian cancer (HBOC) risk-gene variants. Experimental assays scoring p53 functions in transcription and growth control have contributed to variant classification, yet a significant fraction of TP53 variants remain of unknown significance (VUS). To understand whether non-canonical functions of p53 in the fidelity control of DNA replication may aid variant classification, we subjected 23 TP53 VUS and 20 control variants identified in the German Consortium for HBOC (GC-HBOC) to assays that monitor nascent DNA synthesis and recombination-mediated bypass of replication barriers. Our results reveal a clear functional separation between benign (B)/likely benign (LB) and pathogenic (P)/likely pathogenic (LP) variants in recombination measurements, with B/LB variants associated with high recombination frequencies and P/LP variants with low recombination frequencies. Importantly, 8/23 VUS exhibited activities within the B/LB or P/LP ranges and therefore emerge as candidates for revised classification. Variant-specific recombination activities showed significant correlations with functional scores from four earlier studies systematically analyzing canonical p53 functions. Differently, in DNA fiber spreading assays B/LB and P/LP variants showed a more heterogeneous pattern and thus did not consistently recapitulate replication slow-down and acceleration observed in the presence and absence of p53, respectively. Structural modeling of separation-of-function (SOF) variants in transcription and recombination indicates varying effects on protein stability and the conformation of surface-exposed regions, affecting for example, the flexibility of Loop 1 (L1). Intriguingly, individual SOF variants suggest that loss-of-function (LOF) in recombination may drive BC, underscoring the predictive power of this assay for low-penetrance TP53 variants.

#4

Colorectal neoplasia rates in Li Fraumeni Syndrome.

The American journal of gastroenterology2026 Feb 25

Individuals with Li Fraumeni Syndrome (LFS), a cancer predisposition syndrome caused by TP53 pathogenic germline variants (PGV), have an increased risk of colorectal cancer (CRC). However, limited data exists on colonoscopy metrics, including total neoplasia detection rates, in LFS patients. We conducted a retrospective cohort study of colorectal neoplasia incidence and characteristics in 663 individuals with LFS. We determined total neoplasia detection rate, adenoma detection rate (ADR), advanced ADR, serrated lesion detection rate (SDR) and CRC detection rate, stratified by age, gender, and PGV subtype, in 311 surveillance colonoscopies from 206 adults performed January 2019 - August 2024. CRC was reported in 4.5% of 663 adults and 0.8% of 124 pediatric patients with LFS. Among 206 adults undergoing colonoscopy, total neoplasia detection rate, ADR, SDR, advanced precancerous polyp detection rate, and CRC detection rate were 37%, 27%, 9.3%, 4.5%, and 0.64% respectively. Detection rates were similar between loss of function and hypomorphic PGVs. Adults aged 45-75 had higher total neoplasia detection rate, ADR, advanced ADR, SDR, and CRC detection rate than those aged 25-45. Male sex was associated with increased total neoplasia detection rate (53.7% vs. 30.7%, p = 0.0004), ADR (41.2% vs. 22.1%, p = 0.0013), and advanced ADR (7.5% vs. 1.3%, p=0.0105). LFS patients have comparable ADR and higher SDR to average risk adults despite earlier, more frequent surveillance, irrespective of TP53 PGV subtype. Our data support current recommendations for earlier and more frequent colonoscopy surveillance than average-risk guidelines, across LFS phenotypes.

#5

A pan-cancer compendium of 1,294 plasma cell-free DNA methylomes and fragmentomes enabling multicancer detection.

Nature cancer2026 Feb

Cell-free DNA analysis via methylation and fragmentation profiling has advanced minimally invasive cancer detection; however, broader application has been limited by small cohorts and inconsistent data processing. Here we collated 1,074 cfMeDIP-seq profiles across 9 studies, comprising cancer samples from 11 cancer types, carriers of Li-Fraumeni syndrome and healthy controls. We developed a uniform computational workflow to mitigate technical and biological confounders across cohorts. This analysis identified 14,202 pancancer differentially methylated regions for cancer detection, along with cancer-specific markers for subtype monitoring. Fragmentomic profiling revealed distinguishing differences in 5' end motifs, fragment lengths and nucleosome footprints across cancers. Integrating methylome and fragmentome features enhanced cancer detection and classification. Validation in 220 independent samples, including 3 cancer types absent from the primary dataset, confirmed the robustness of our findings. Altogether, this work provides a pancancer cell-free DNA resource of 1,294 samples to support future methylome and fragmentome studies.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC662 artigos no totalmostrando 199

2026

Back pain in an adolescent: not just a sore spine!

Ecancermedicalscience
2026

Neurogenetic tumor syndromes: The current landscape of workup and treatment.

Neuro-oncology practice
2025

A brief feasibility report on an online psychosocial support intervention for adults with Li-Fraumeni syndrome.

Frontiers in psychology
2026

Tumor patterns and cancer risk in carriers of TP53 exonic germline variants that alter mRNA splicing.

European journal of human genetics : EJHG
2026

Evaluation of non-canonical p53 functions in DNA replication and recombination for variant classification.

Cell death &amp; disease
2026

Exceptional Response to a Single Dose of Pembrolizumab as Salvage Therapy for Metastatic Adrenocortical Carcinoma.

JCEM case reports
2026

SIGNIFIED: whole-body MRI screening in Li-Fraumeni syndrome in the UK.

ESMO open
2026

Colorectal neoplasia rates in Li Fraumeni Syndrome.

The American journal of gastroenterology
2026

Late-Onset Li-Fraumeni Syndrome-Like Phenotype Presenting With Synchronous Lung Adenocarcinoma and Ovarian High-Grade Serous Carcinoma: A Case Report.

Cureus
2026

Concordance analysis of DNA and RNA profiling: The MD Anderson IMPACT2 study in precision oncology.

Signal transduction and targeted therapy
2026

A pan-cancer compendium of 1,294 plasma cell-free DNA methylomes and fragmentomes enabling multicancer detection.

Nature cancer
2026

Hereditary Endometrial Cancer: Lynch Syndrome, Mismatch Repair Deficiency, and Emerging Genetic Predispositions-A Comprehensive Review with Clinical and Laboratory Guidelines.

International journal of molecular sciences
2025

Evaluation of Germline Pathogenic Variant of TP53 Gene in an Iranian Pedigree with Familial Sarcoma: A Case Report.

Advanced biomedical research
2026

Radiotherapy in Li-Fraumeni Syndrome: From Biological Concern to Personalized Clinical Decision-Making.

Cureus
2026

Unraveling syndrome-driven osteosarcoma: genetic insights and therapeutic frontiers.

Orphanet journal of rare diseases
2026

Ultra-deep duplex sequencing reveals unique features of somatic evolution in the normal tissues of a family with Li-Fraumeni syndrome.

bioRxiv : the preprint server for biology
2026

Attenuated Li-Fraumeni syndrome with TP53 p.R181H in a Japanese patient with metastatic rectal adenocarcinoma: a case report.

Familial cancer
2026

Digital Health Tools Embedded in a Cancer Genetics Clinic: Observational Study.

JMIR formative research
2026

Mosaic Li Fraumeni Syndrome Not Identified in Germinal Tissue.

Molecular genetics &amp; genomic medicine
2026

Non-invasive screening in hereditary cancer: a randomized controlled trial to test cell-free DNA-based early detection in the CHARM consortium.

European journal of human genetics : EJHG
2026

Preclinical drug screen identifies WEE1 inhibitor and vinca alkaloid as a combination treatment concept for Li-Fraumeni syndrome medulloblastoma.

iScience
2025

Subsequent primary and secondary neoplasms in childhood cancer survivors.

Polish journal of radiology
2026

Urgent need to recognize that Disease-Causing TP53 variants with atypical penetrance require distinct clinical recommendations.

Journal of the National Cancer Institute
2025

Radiation-induced sarcoma after glioma resection in patients with Li-Fraumeni syndrome: illustrative cases.

Journal of neurosurgery. Case lessons
2026

Clonal Profiles in a Li-Fraumeni Syndrome Patient With SHH Medulloblastoma: Clonal Evolution, Genomics, and Clinical Implications.

Pediatric blood &amp; cancer
2026

Adrenocortical Carcinoma With Right Atrial Extension in a Three-Year-Old Child: A Case Report.

Cureus
2026

Thoracic chordoma following intracranial meningioma in a patient with a novel germline SMARCE1 variant.

European journal of medical genetics
2025

[Establishment of a Treatment System for Hereditary Breast Cancer in Our Hospital].

Gan to kagaku ryoho. Cancer &amp; chemotherapy
2026

Genetic Profiling of Mammary Periductal Stromal Tumors With Histologic Correlation Highlights High-Grade and Low-Grade Groups and Similarities to Phyllodes Tumors.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
2026

Genetic tumor syndromes in female cancer: insights into inherited cancer predisposition and clinical implications.

Archives of gynecology and obstetrics
2026

App supporting surveillance for (likely) pathogenic TP53 variant carriers: acceptance among a German cohort.

Archives of gynecology and obstetrics
2026

Clinical Features and Treatment Strategies of Li-Fraumeni Syndrome Patients With Inherited TP53 Mutations.

Molecular genetics &amp; genomic medicine
2026

The p53 R181C mutation accumulates through impaired deacetylation by Sirt1 and facilitates tumor development.

Communications biology
2026

Myxoid Pleomorphic Liposarcoma: A Review and Update.

Cancer genomics &amp; proteomics
2026

Oral squamous cell carcinoma risk and magnitude of association in inherited cancer predisposition syndromes: evidence from a large real-world cohort.

Oral surgery, oral medicine, oral pathology and oral radiology
2026

Genotype-Phenotype Correlations of Li-Fraumeni Syndrome in Japan Children's Cancer Group LFS20 Study Cohort.

Cancer science
2026

Clinical Significance of Molecular Genetic Analysis in Diffuse Intrinsic Pontine Glioma: Two Case Reports.

Pediatric blood &amp; cancer
2025

Description of six cases of melanoma in 512 patients with germline pathogenic variants in the TP53 gene.

Familial cancer
2025

Precision Care for Hereditary Urologic Cancers: Genetic Testing, Counseling, Surveillance, and Therapeutic Implications.

Current oncology (Toronto, Ont.)
2025

Mice carrying nonsense mutant p53 develop frequent multicentric or metastatic tumors.

Cell death &amp; disease
2026

Neoantigenic properties of TP53 variants influence cancer risk in individuals with Li-Fraumeni syndrome.

EBioMedicine
2025

[Analysis of clinicopathological and genetic characteristics of three cases of Li-Fraumeni syndrome].

Zhonghua bing li xue za zhi = Chinese journal of pathology
2025

Characterization of p53 p.T253I as a pathogenic mutation underlying Li-Fraumeni Syndrome.

PloS one
2025

Skin cancer risk in hereditary mixed cancer syndromes.

Hereditary cancer in clinical practice
2025

Psychosocial burdens and unmet supportive care needs of partners and relatives of individuals with Li-Fraumeni syndrome: A mixed-methods study.

Journal of genetic counseling
2025

Making Sense of Missense: Assessing and Incorporating the Functional Impact of Constitutional Genetic Testing.

Children (Basel, Switzerland)
2025

Transfer Learning for Survival-based Clustering of Predictors with an Application to TP53 Mutation Annotation.

bioRxiv : the preprint server for biology
2025

Concerns about the consequences of cancer predisposition and relationships with quality of life in young adults with Li-Fraumeni syndrome.

European journal of human genetics : EJHG
2025

Clinical challenges of cancer predisposition syndromes with pediatric central nervous system tumors: a single-center study.

Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
2026

Surgical Management and Outcomes in Pediatric Adrenocortical Carcinoma: A Pediatric Surgical Oncology Research Collaborative Study.

Annals of surgical oncology
2025

Segregation of the rare TP53 germline missense variant c.314G>T, p.Gly105Val in Algerian family with Li-Fraumeni Syndrome: First report.

Cancer genetics
2025

Germline Predisposition to Pediatric Lymphoid Malignancies: Genetic Tumor Syndromes Identified in a Single-Center Study.

Clinical laboratory
2025

Genomic Instability in Hereditary Breast Cancer: Clinical and Nursing Implications for Risk Assessment and Targeted Therapeutic Strategies.

Seminars in oncology nursing
2025

An overview of the diagnosis and management of Choroid Plexus tumors.

Advances in cancer research
2026

Melanoma of the Choroid and Ciliary Body in Children: Remission of Metastatic Melanoma of the Choroid After Treatment With Chemotherapy and Immune Checkpoint Inhibition.

Pediatric blood &amp; cancer
2025

Knowledge Mobilization Efforts by Global Pediatric Oncology Civil Society Organizations: An Environmental Scan Protocol.

Sage open pediatrics
2025

Hypopharyngeal squamous cell carcinoma in a patient with germline TP53 c.743G > A (p.Arg248Gln) variant: a case report.

Journal of medical case reports
2025

Changes in the approach to the analysis and evaluation of inherited pathogenic TP53 variants.

Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti
2026

Reconstructing the Origin and Demographic Expansion of the TP53 p.R337H Founder Variant in Brazil.

Cancer epidemiology, biomarkers &amp; prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
2025

Multiple Primary Cancers as an Independent Criterion for Germline Testing: Comparison with Guideline-Based Criteria.

Journal of clinical medicine
2025

Prospective Study of Annual Whole-Body Magnetic Resonance Imaging as Part of a Multimodality Screening Program for Individuals With Li-Fraumeni Syndrome.

JCO precision oncology
2025

A quantitative, Bayesian-informed approach to gene-specific variant classification: Updated Expert Panel recommendations improve classification of TP53 germline variants for Li-Fraumeni syndrome.

Genome medicine
2025

Optimizing whole-body MRI for early cancer detection in Li-Fraumeni syndrome: a prospective bicentric study.

European radiology
2026

[Unexpected liver tumors in a patient with Li-Fraumeni syndrome].

Annales de pathologie
2025

TP53 p.R181H is enriched in the Swedish cohort (SWEP53) and associated with a distinct breast and prostate phenotype.

Scientific reports
2025

Shared decision-making in radiology: leadership levers for patient-centred imaging.

BMJ leader
2025

Rapidly Progressive Metastatic Adrenocortical Carcinoma With Oncocytic Features in a Young Male: A Case Report.

Cureus
2025

Cancer Predisposition Syndromes With Involvement of the Head and Neck Regions in Children: An Imaging Guide.

Journal of neuroimaging : official journal of the American Society of Neuroimaging
2025

TP53 variant clusters stratify phenotypic diversity in germline carriers and reveal an osteosarcoma-prone subgroup.

Nature communications
2025

Revisiting pediatric HGGs and PNETs according to the WHO CNS5 criteria: A clinical and genomic retrospective analysis.

Neuro-oncology advances
2026

Aqueductal posterior fossa type B ependymoma in Li-Fraumeni syndrome.

Journal of neuropathology and experimental neurology
2025

Li-Fraumeni Syndrome-Associated p53 Variants Disrupt Kidney and Urinary Tract Development.

medRxiv : the preprint server for health sciences
2025

Relational Aspects to Screening-Associated Distress Among Individuals With Li-Fraumeni Syndrome: "The All-Clear for Me Is Good. The All-Clear for My Kids Is Great".

Qualitative health research
2025

A phase I study of AZD8186 in combination with docetaxel in patients with PTEN-mutated or PIK3CB-mutated advanced solid tumors.

ESMO open
2025

Prospective characterization of germline variants in patients with gliomas and glioneuronal tumors.

Acta neuropathologica
2025

Navigating disclosure in new romantic partnerships as an adolescent or young adult with Li-Fraumeni syndrome.

Familial cancer
2025

Multiple early onset atypical cutaneous fibrous histiocytomas in multilocus inherited neoplasia allele syndrome involving TP53 and FLCN genes.

Journal of medical genetics
2025

Multihit Somatic Mosaicism of TP53 Pathogenic Variants in a Patient Mimicking Li-Fraumeni Syndrome.

JCO precision oncology
2025

Dissecting cross-lineage tumourigenesis under p53 inactivation through single-cell multi-omics and spatial transcriptomics.

Clinical and translational medicine
2025

Peripheral blood DNA methylation predicts the early onset of primary tumor in TP53 mutation carriers.

Nature communications
2025

Li Fraumeni syndrome in the UK: clinical characteristics and outcomes of TP53 carriers.

ESMO open
2025

Variation at the R181 residue of p53 confers loss of p53 DNA binding cooperativity with the retention of mitochondrial-associated apoptosis.

bioRxiv : the preprint server for biology
2025

In-frame germline TP53 variant impairs p53 oligomerization and predisposes to cancer.

Scientific reports
2025

A rare pediatric case of Li-Fraumeni syndrome presenting with virilization symptoms and dual primary malignancies on magnetic resonance imaging and [18F]-fluorodeoxyglucose positron emission tomography/computed tomography.

Pediatric radiology
2025

Metastatic Pheochromocytoma in a Patient With Li-Fraumeni Syndrome.

JCEM case reports
2025

Dominant-Negative Effects of p53 R337 Variants in Li-Fraumeni Syndrome: Impact on Tetramer Formation and Transcriptional Activity.

Chembiochem : a European journal of chemical biology
2025

'I told them they had to get tested, and they did': social influence among siblings with Li-Fraumeni syndrome.

Psychology &amp; health
2025

Characteristics predicting reduced penetrance variants in the high-risk cancer predisposition gene TP53.

HGG advances
2025

Risk factors for secondary neoplasms in retinoblastoma survivors: a systematic literature review.

Expert review of anticancer therapy
2025

Evaluation of whole-body MRI for cancer early detection in Li-Fraumeni syndrome.

Journal of medical genetics
2025

p53 prophylactic therapy for cancer prevention.

Cell death and differentiation
2025

Germline TP53 p.R337H and XAF1 p.E134* Variants: Prevalence in Paraguay and Comparison with Rates in Brazilian State of Paraná and Previous Findings at the Paraguayan-Brazilian Border.

Current oncology (Toronto, Ont.)
2025

Epithelial Abnormalities in the High-Risk Fallopian Tube of a Rare TP53/BRCA2 Li-Fraumeni Syndrome Patient With Multiple Tumors.

JCO precision oncology
2025

Transmission ratio distortion of germline TP53 variants in Li-Fraumeni syndrome families.

Cancer
2025

The argument for screening programs in previvors with Li-Fraumeni syndrome.

Expert review of anticancer therapy
2025

Hematologic Malignancy Frequency, Phenotypes, and Outcomes in Li-Fraumeni Syndrome.

JCO precision oncology
2026

Allergic Reaction to a Bovine-Derived Dural Graft without Eosinophilic Meningitis : A Case Report and Literature Review.

Journal of Korean Neurosurgical Society
2025

Deciphering dual clinical entities associated with TP53 pathogenic variants: Insights from 53,085 HBOC panel analyses in French laboratories.

International journal of cancer
2025

Optimizing shared decision-making for risk-reducing mastectomy in women with Li-Fraumeni syndrome using patient-reported outcome measures.

Scientific reports
2025

Paediatric HeartMate 3 implant due to anthracycline-induced cardiomyopathy.

Multimedia manual of cardiothoracic surgery : MMCTS
2025

Cancer Predisposition Syndromes Associated with Most Common Pediatric Solid Tumors.

Surgical pathology clinics
2025

Deciphering TP53 Mosaic Variants on Germline Biomarker Testing: Implications for Oncology Nurses.

Clinical journal of oncology nursing
2025

UK clinical practice guidelines for the management of patients with constitutional POT1 pathogenic variants.

Journal of medical genetics
2025

Li-Fraumeni Syndrome : Current Strategies and Future Perspectives.

Journal of Korean Neurosurgical Society
2025

Clinical classification and molecular interpretation of germline pathogenic TP53 variations detected by multigene panel testing in patients with possible cancer predisposition.

Molecular genetics and genomics : MGG
2025

Paediatric urachal rhabdomyosarcoma: the role of radiotherapy about a case report and review.

Ecancermedicalscience
2025

Targeting pediatric adrenocortical carcinoma: Molecular insights and emerging therapeutic strategies.

Cancer treatment reviews
2025

Adjuvant Radiotherapy and Breast Cancer in Patients with Li-Fraumeni Syndrome: A Critical Review.

Cancers
2025

Early-onset Colorectal Cancer in a Patient with Li-Fraumeni Syndrome: A Case Series and Literature Review.

Internal medicine (Tokyo, Japan)
2025

Myxoid liposarcoma of thyroid in a 10-year-old child with Li-Fraumeni syndrome: A case report and review of literature.

Journal of cancer research and therapeutics
2025

Oncocytic Tumors in the Familial and Syndromic Contexts: A Tri-Focal Review - Integrated Cytopathological, Pathological, and Molecular Perspectives.

Acta cytologica
2025

Utility of Whole-Body Magnetic Resonance Imaging Surveillance in Children and Adults With Cancer Predisposition Syndromes: A Retrospective Study.

JCO precision oncology
2025

[Pathogenic large duplication in TP53 as a hereditary predisposing factor in breast cancer].

Magyar onkologia
2025

Corrigendum to "HER2 status and response to neoadjuvant anti-HER2 treatment among patients with breast cancer and Li-Fraumeni syndrome" [Eur J Cancer 211 (2024) 114307].

European journal of cancer (Oxford, England : 1990)
2025

Update on Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome.

Clinical cancer research : an official journal of the American Association for Cancer Research
2025

A systematic review of high-grade glioma associated with Li-Fraumeni syndrome.

Neurosurgical review
2025

Radiotherapy results in decreased time to second cancer in children with Li Fraumeni syndrome.

Journal of the National Cancer Institute
2025

Mis-splicing drives loss of function of p53E224D point mutation.

PloS one
2025

Pan-cancer multi-omic model of LINE-1 activity reveals locus heterogeneity of retrotransposition efficiency.

Nature communications
2025

Pancreatic Cancer Risk and Screening Outcomes in Li-Fraumeni Syndrome.

Pancreas
2025

Clinical Characteristics and Chemosensitivity in Germline TP53 Pathogenic Variant Cases Identified by Cancer Genomic Testing.

Cancer genomics &amp; proteomics
2025

Bone tumors: a systematic review of prevalence, risk determinants, and survival patterns.

BMC cancer
2025

Assessing germline TP53 mutations in cancer patients: insights into Li-Fraumeni syndrome and genetic testing guidelines.

Hereditary cancer in clinical practice
2025

[EMERGING THERAPIES FOR LI-FRAUMENI SYNDROME AND RHABDOMYOSARCOMA: CAN CHAT GPT ASSESS THE THERAPIES IT SUGGESTS USING THE BRADFORD-HILL CRITERIA?].

Harefuah
2025

EGFR-Mutated Lung Adenocarcinoma With Li-Fraumeni Syndrome: The Imperative for Germline Testing in Patients With a Family History, a Case Report.

JTO clinical and research reports
2025

Personalized screening strategies for TP53 R337H carriers: a retrospective cohort study of tumor spectrum in Li-Fraumeni syndrome adult carriers.

Lancet regional health. Americas
2025

Cancer risk in carriers of TP53 germline variants grouped into different functional categories.

JNCI cancer spectrum
2025

A case of Li-Fraumeni syndrome caused by a 3.6 kb deletion in the TP53 gene suggested by additional data from the NCC Oncopanel.

Japanese journal of clinical oncology
2025

Case review of perivascular epithelioid cell tumor occurring in patients with Li-Fraumeni syndrome.

Familial cancer
2025

Bone sarcomas and cancer predisposition syndromes.

Bulletin du cancer
2025

Exploiting somatic oncogenic driver alterations in a patient with Li-Fraumeni syndrome- paving the path towards precision medicine: a case report.

Journal of cancer research and clinical oncology
2025

Pediatric high-grade gliomas with concomitant RB1 and SETD2 alterations and Li-Fraumeni syndrome.

Acta neuropathologica communications
2025

TP53 germline testing and hereditary cancer: how somatic events and clinical criteria affect variant detection rate.

Genome medicine
2025

Li-Fraumeni syndrome: a germline TP53 splice variant reveals a novel physiological alternative transcript.

Journal of medical genetics
2025

Characterisation of heritable TP53-related cancer syndrome in Sweden-a nationwide study of genotype-phenotype correlations in 90 families.

European journal of human genetics : EJHG
2024

New Germline TP53 Variant Detected After Radiotherapy-Induced Angiosarcoma of the Chest Wall in a Previously Treated Breast Cancer Patient: A Case Report and Review of Li-Fraumeni Syndrome and Radiotherapy-Induced Sarcoma.

Case reports in oncological medicine
2025

TP53 missense allele predisposing to high risk of breast cancer but not pediatric cancers.

Journal of the National Cancer Institute
2024

[Research progress on pathogenic germline mutations in malignant tumors].

Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
2025

tp53 R217H and R242H mutant zebrafish exhibit dysfunctional p53 hallmarks and recapitulate Li-Fraumeni syndrome phenotypes.

Biochimica et biophysica acta. Molecular basis of disease
2024

Clustering of TP53 variants into functional classes correlates with cancer risk and identifies different phenotypes of Li-Fraumeni syndrome.

iScience
2025

Clinicopathologic Features of Breast Tumors in Germline TP53 Variant-Associated Li-Fraumeni Syndrome.

The American journal of surgical pathology
2024

Tricuspid mass-curious case of Li-Fraumeni syndrome: A letter to the editor.

World journal of clinical cases
2024

Long-term survival in a patient with Li-Fraumeni syndrome-associated giant cell glioblastoma treated with nivolumab: illustrative case.

Journal of neurosurgery. Case lessons
2024

Characterization of sarcoma topography in Li-Fraumeni syndrome.

Frontiers in oncology
2025

Adrenocortical tumors and hereditary syndromes.

Expert review of endocrinology &amp; metabolism
2024

Case report: Efficacy of later-line fam-trastuzumab deruxtecan in a patient with triple-positive breast cancer with brain metastases.

Frontiers in oncology
2025

What Is the Cost: Financial Toxicity and Screening Fatigue in Li-Fraumeni Syndrome.

Cancer prevention research (Philadelphia, Pa.)
2024

BRCA2 and TP53 Mutations in a Breast Cancer Patient: A Case Report and Review of the Literature.

Cureus
2024

Double Heterozygous Pathogenic Variants in TP53 and CHEK2 in Boy with Undifferentiated Embryonal Sarcoma of the Liver.

International journal of molecular sciences
2024

Li-Fraumeni Syndrome: Narrative Review Through a Case Report with Ten Years of Primary Tumor Remission Associated with Sechium H387 07 Supplementation.

International journal of molecular sciences
2024

Complexity in interpreting cardiac valve-associated thrombus from tumors in Li-Fraumeni syndrome.

World journal of clinical cases
2024

Genetic predisposition to myelodysplastic syndrome: Genetic counseling and transplant implications.

Seminars in hematology
2024

Osteosarcoma patient with Li-Fraumeni syndrome: the first case report in Vietnam.

Frontiers in oncology
2024

TP53 variants underlying pediatric low-hypodiploidy B-cell acute lymphoblastic leukemia demonstrate diverse origins and may persist as a hematopoietic clone in remission.

EJHaem
2024

Current insights and future directions of Li-Fraumeni syndrome.

Discover oncology
2024

Li-Fraumeni-associated osteosarcomas: The French experience.

Pediatric blood &amp; cancer
2024

The spectrum of hematologic neoplasms in patients with Li-Fraumeni syndrome.

American journal of hematology
2024

The molecular genetics of adrenal cushing.

Hormones (Athens, Greece)
2024

Adrenocortical neoplasm in a 2-year-old child: Clinical approach and diagnostic imaging.

Radiology case reports
2024

Genetic Predisposition for Gynecologic Cancers.

Clinical obstetrics and gynecology
2024

CHEK2 mutation causes manifestations similar to Lynch syndrome and Li-Fraumeni syndrome.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
2024

The Prevalence of Cancer Predisposition Syndromes (CPSs) in Children with a Neoplasm: A Cohort Study in a Central and Eastern European Population.

Genes
2025

Relating to the Body Under Chronic Cancer Threat: Implications for Psychosocial Health Among Adolescents and Young Adults with Cancer Predisposition Syndromes.

Journal of adolescent and young adult oncology
2024

Her2-positive breast cancer in a young patient with Li-Fraumeni syndrome: A comprehensive case study.

International journal of surgery case reports
2024

Germline variant affecting p53β isoforms predisposes to familial cancer.

Nature communications
2024

Orthopedic manifestations of Li-Fraumeni syndrome: Prevention and treatment of a polymorphic spectrum of malignancies.

World journal of clinical cases
2024

Laparoscopic resection of liver PEComa associated with Li‑Fraumeni syndrome: A case report.

Biomedical reports
2024

Germline p.R181H variant in TP53 in a family exemplifying the genotype-phenotype correlations in Li-Fraumeni syndrome.

Familial cancer
2024

HER2 status and response to neoadjuvant anti-HER2 treatment among patients with breast cancer and Li-Fraumeni syndrome.

European journal of cancer (Oxford, England : 1990)
2024

A dual biomarker in non-small cell lung cancer that predicts Li Fraumeni syndrome : Lung cancer and Li Fraumeni.

Familial cancer
2024

Value of Engagement in Digital Health Technology Research: Evidence Across 6 Unique Cohort Studies.

Journal of medical Internet research
2024

Imaging features of pediatric angiosarcomas: clinical, pathologic, and radiological review.

Pediatric radiology
2024

Genetic hallmarks and clinical implications of chromothripsis in childhood T-cell acute lymphoblastic leukemia.

Leukemia
2024

Cell-free DNA from germline TP53 mutation carriers reflect cancer-like fragmentation patterns.

Nature communications
2024

Diagnostic challenges from conflicting results of tests and imaging.

World journal of clinical cases
2024

Patterns of Growth of Tumors in Li-Fraumeni Syndrome by Imaging: A Case Series.

Journal of pediatric hematology/oncology
2024

The Impact of Li-Fraumeni and Germline Retinoblastoma Mutations on Leiomyosarcoma Initiation, Outcomes, and Genetic Testing Recommendations.

Clinical cancer research : an official journal of the American Association for Cancer Research
2024

Generation of two induced pluripotent stem cell lines from patients with Li-Fraumeni Syndrome carrying TP53 mutation.

Stem cell research
2024

"I Just Assumed This Was Already Being Done": Canadian Patient Preferences for Enhanced Data Sharing for Precision Oncology.

JCO precision oncology
2024

Papillary Thyroid Carcinoma, Cushing Disease, and Adrenocortical Carcinoma in a Patient with Li-Fraumeni Syndrome.

AACE clinical case reports
2024

EGFR-mutated lung cancer as a secondary neoplasm in a patient with Li-Fraumeni syndrome: case report.

AME case reports
2024

Characterizing Lung Cancer in Li-Fraumeni Syndrome.

JAMA oncology
2025

Narrative review on ethical and psychological issues raised by genetic and genomic testing in pediatric oncology care.

Journal of genetic counseling
2025

Baseline surveillance in Li Fraumeni syndrome using whole-body MRI: a systematic review and updated meta-analysis.

European radiology
2025

Ocular adnexal sebaceous carcinoma in a patient with Li-Fraumeni syndrome.

Orbit (Amsterdam, Netherlands)
2024

TP53 p.R337H Germline Variant among Women at Risk of Hereditary Breast Cancer in a Public Health System of Midwest Brazil.

Genes
2024

Functional evaluation of germline TP53 variants identified in Brazilian families at-risk for Li-Fraumeni syndrome.

Scientific reports
2024

Performance of LFSPRO TP53 germline carrier risk predictions compared to standard genetic counseling practice on prospectively collected probands.

medRxiv : the preprint server for health sciences
2024

Marrow-ablative consolidation chemotherapy and molecular targeted therapy delivered in a risk-adapted manner for newly diagnosed children with choroid plexus carcinoma: A work in progress.

Neuro-oncology advances
2024

Adrenal cortical carcinoma: Paediatric aspects - literature review.

Pediatric endocrinology, diabetes, and metabolism
2024

Li-Fraumeni Syndrome: Imaging Features and Guidelines.

Radiographics : a review publication of the Radiological Society of North America, Inc
2024

Selective pressures of platinum compounds shape the evolution of therapy-related myeloid neoplasms.

Nature communications
2024

Case series of Li-Fraumeni syndrome: carcinogenic mechanisms in breast cancer with TP53 pathogenic variant carriers.

Breast cancer (Tokyo, Japan)
2025

Virilizing adrenocortical carcinoma in a female child of Li-Fraumeni syndrome.

Indian journal of pathology &amp; microbiology
2024

Case report: TP53 c.848G>A germline mutation as a possible screening target at initial diagnosis for acute lymphoblastic leukemia.

Hematology (Amsterdam, Netherlands)
2024

Overall approaches to cardiac tumors: Still an unsolved enigma?

World journal of clinical cases
2024

Diagnostic and Practical Challenges in Applying National Comprehensive Cancer Network Guidelines for Suspected Pathogenic TP53 Mosaicism.

JCO precision oncology
2024

Whole-body MRI in oncology: acquisition protocols, current guidelines, and beyond.

La Radiologia medica
2024

Metformin beyond type 2 diabetes: Emerging and potential new indications.

Diabetes, obesity &amp; metabolism
Ver todos os 662 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Síndrome Li-Fraumeni.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Síndrome Li-Fraumeni

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Back pain in an adolescent: not just a sore spine!
    Ecancermedicalscience· 2026· PMID 41877742mais citado
  2. Tumor patterns and cancer risk in carriers of TP53 exonic germline variants that alter mRNA splicing.
    European journal of human genetics : EJHG· 2026· PMID 41776348mais citado
  3. Evaluation of non-canonical p53 functions in DNA replication and recombination for variant classification.
    Cell death &amp; disease· 2026· PMID 41764184mais citado
  4. Colorectal neoplasia rates in Li Fraumeni Syndrome.
    The American journal of gastroenterology· 2026· PMID 41738599mais citado
  5. A pan-cancer compendium of 1,294 plasma cell-free DNA methylomes and fragmentomes enabling multicancer detection.
    Nature cancer· 2026· PMID 41714824mais citado
  6. Performance of LFSPRO prediction in TP53 mutation status for prospectively collected probands.
    Am J Hum Genet· 2026· PMID 41990740recente
  7. Liquid Biopsy for Cancer Screening in Li-Fraumeni Syndrome: Interest in Clinical Trial and Reported Barriers to Standard of Care Screening.
    Cancer Prev Res (Phila)· 2026· PMID 41984087recente
  8. Opportunistic identification of Li-Fraumeni syndrome through germline TP53 variant detection from routine tumour next-generation sequencing: An analysis of 1394 cases.
    Rev Esp Patol· 2026· PMID 41922118recente
  9. Genotoxic Chemotherapy in Li-Fraumeni Syndrome: Molecular Mechanisms, Clinical Consequences, and Alternative Therapeutic Strategies.
    Curr Pharm Des· 2026· PMID 41919425recente
  10. Young-onset rectal adenocarcinoma in Li-Fraumeni syndrome: Diagnostic contribution of NBI and pit pattern analysis.
    Dig Liver Dis· 2026· PMID 41916830recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:524(Orphanet)
  2. OMIM OMIM:151623(OMIM)
  3. MONDO:0018875(MONDO)
  4. GARD:6902(GARD (NIH))
  5. Variantes catalogadas(ClinVar)
  6. Busca completa no PubMed(PubMed)
  7. Artigo Wikipedia(Wikipedia)
  8. Q187542(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Síndrome Li-Fraumeni
Compêndio · Raras BR

Síndrome Li-Fraumeni

ORPHA:524 · MONDO:0018875
Prevalência
Unknown
Herança
Autosomal dominant
CID-10
C97 · Neoplasias malignas de localizações múltiplas independentes (primárias)
CID-11
Ensaios
13 ativos
Medicamentos
1 registrados
Início
All ages
Prevalência
7.0 (United Kingdom)
MedGen
UMLS
C0085390
EuropePMC
Wikidata
Wikipedia
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades